Terms: = Prostate cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
213 results:
1. Prognostic significance of tumor suppressor protein p53 in prostate cancer.
Ben Rejeb S; Kouki N; Elfekih S; Cherif I; Khouni H
Tunis Med; 2024 Feb; 102(2):111-115. PubMed ID: 38567478
[TBL] [Abstract] [Full Text] [Related]
2. The impact of telomere length on prostate cancer aggressiveness, genomic instability and health disparities.
Huang R; Bornman MSR; Stricker PD; Simoni Brum I; Mutambirwa SBA; Jaratlerdsiri W; Hayes VM
Sci Rep; 2024 Apr; 14(1):7706. PubMed ID: 38565642
[TBL] [Abstract] [Full Text] [Related]
3. STEAP3 Affects Ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
[TBL] [Abstract] [Full Text] [Related]
4. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
5. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
[TBL] [Abstract] [Full Text] [Related]
6. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive analysis of integrin αvβ3/α6β1 in prognosis and immune escape of prostate cancer.
Liu Y; He JX; Ji B; Wang JF; Zhang L; Pang ZQ; Wang JS; Ding BC; Ren MH
Aging (Albany NY); 2023 Oct; 15(20):11369-11388. PubMed ID: 37862114
[TBL] [Abstract] [Full Text] [Related]
8. tp53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
[TBL] [Abstract] [Full Text] [Related]
9. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.
Agarwal S; Fang L; McGowen K; Yin J; Bowman J; Ku AT; Alilin AN; Corey E; Roudier MP; True LD; Dumpit R; Coleman I; Lee JK; Nelson PS; Capaldo BJ; Mariani A; Hoover C; Senatorov IS; Beshiri M; Sowalsky AG; Hurt EM; Kelly K
J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37725435
[TBL] [Abstract] [Full Text] [Related]
11. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers.
Quintanal-Villalonga A; Durani V; Sabet A; Redin E; Kawasaki K; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Shah NS; Chow A; Bhanot UK; Linkov I; Asher M; Yu HA; Qiu J; de Stanchina E; Patel RA; Morrissey C; Haffner MC; Koche RP; Sawyers CL; Rudin CM
Sci Transl Med; 2023 Aug; 15(707):eadf7006. PubMed ID: 37531417
[TBL] [Abstract] [Full Text] [Related]
12. Delta/Notch-like Epidermal Growth Factor-Related Receptor (DNER), a Potential Prognostic Marker of Gastric cancer Regulates Cell Survival and Cell Cycle Progression.
To HTN; Park JH; Kim JW; Kang D
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373228
[TBL] [Abstract] [Full Text] [Related]
13. Long noncoding RNA MIAT regulates tp53 ubiquitination and expedites prostate adenocarcinoma progression by recruiting TBL1X.
Gong Z; Zhang H; Ge Y; Wang P
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119527. PubMed ID: 37356458
[TBL] [Abstract] [Full Text] [Related]
14. Whole Slide Imaging-Based Prediction of tp53 Mutations Identifies an Aggressive Disease Phenotype in prostate cancer.
Pizurica M; Larmuseau M; Van der Eecken K; de Schaetzen van Brienen L; Carrillo-Perez F; Isphording S; Lumen N; Van Dorpe J; Ost P; Verbeke S; Gevaert O; Marchal K
Cancer Res; 2023 Sep; 83(17):2970-2984. PubMed ID: 37352385
[TBL] [Abstract] [Full Text] [Related]
15. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a potential prognostic biomarker in clear cell renal cell carcinoma that correlates with M2 macrophage infiltration and epithelial-mesenchymal.
Wei H; Li Z; Zhao Y; Zhu S; Wen S; Quan C
Cancer Rep (Hoboken); 2023 Aug; 6(8):e1824. PubMed ID: 37344930
[TBL] [Abstract] [Full Text] [Related]
16. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine prostate cancer Coexisting with Androgen Receptor Pathway prostate cancer.
Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
[TBL] [Abstract] [Full Text] [Related]
17. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.
Ji Y; Liu B; Chen L; Li A; Shen K; Su R; Zhang W; Zhu Y; Wang Q; Xue W
Cell Oncol (Dordr); 2023 Oct; 46(5):1445-1456. PubMed ID: 37120492
[TBL] [Abstract] [Full Text] [Related]
18. Overexpression of DDX49 in prostate cancer is associated with poor prognosis.
Tao J; Ge Q; Meng J; Liang C; Hao Z; Zhou J
BMC Urol; 2023 Apr; 23(1):66. PubMed ID: 37106339
[TBL] [Abstract] [Full Text] [Related]
19. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient prostate cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract] [Full Text] [Related]
20. Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases.
Padilla A; Manganaro JF; Huesgen L; Roess DA; Brown MA; Crans DC
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838987
[TBL] [Abstract] [Full Text] [Related]
[Next]
